Skip to main content
. Author manuscript; available in PMC: 2021 May 15.
Published in final edited form as: Antiviral Res. 2017 Aug 24;146:139–145. doi: 10.1016/j.antiviral.2017.08.016

Fig. 2. IP-10 levels of patients with and without previous RG-101 dosing.

Fig. 2

(2A) Baseline IP-10 levels in patients with (black dots) and without (grey dots) previous RG-101 dosing and healthy controls (HC, white triangles), median and interquartile range are shown. Mann-Whitney U test was used to compare study groups. (1B) IP-10 levels in CHC patient throughout the study period up to follow-up week 24 (FU24), median and interquartile range are shown. Mann-Whitney U test was used to compare study groups. LLOQ, lower limit of quantification. *p < 0,05; ***p < 0.001; ****p < 0,0001.